57 Chemin du Lavoir, 01630 Sergy Haut, France.
Expert Rev Vaccines. 2011 Aug;10(8):1143-67. doi: 10.1586/erv.11.99. Epub 2011 Aug 3.
Vaccination is the only public-health measure likely to reduce the burden of pneumococcal diseases. In 2010, a group of European experts reviewed evidence on the burden of pneumococcal disease and the immunogenicity, clinical effectiveness and cost-effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23). They also considered issues affecting the future use of PPV23 and pneumococcal conjugate vaccines in the elderly and adults at high risk of pneumococcal disease. PPV23 covers 80-90% of the serotypes responsible for invasive pneumococcal disease in Europe. Primary vaccination and revaccination with PPV23 are well tolerated, induce robust, long-lasting immune responses in elderly adults and are cost effective. Ensuring protection against pneumococcal disease requires monitoring of the changing epidemiology of pneumococcal serotypes causing invasive pneumococcal disease and improving vaccine coverage. In the future, it will be critically important for pneumococcal vaccination recommendations for elderly adults to be based on comparative evaluations of PPV23 and newer pneumococcal conjugate vaccines with regard to their long-term immunogenicity, clinical effectiveness and cost-effectiveness.
疫苗接种是减轻肺炎球菌疾病负担的唯一公共卫生措施。2010 年，一组欧洲专家对肺炎球菌疾病的负担以及 23 价肺炎球菌多糖疫苗（PPV23）的免疫原性、临床效果和成本效益进行了评估。他们还考虑了影响未来在老年人和肺炎球菌疾病高危人群中使用 PPV23 和肺炎球菌结合疫苗的问题。PPV23 涵盖了欧洲侵袭性肺炎球菌疾病 80-90%的血清型。PPV23 的初次接种和加强接种耐受性良好，能在老年人中诱导出强大、持久的免疫应答，具有成本效益。要确保预防肺炎球菌疾病，需要监测导致侵袭性肺炎球菌疾病的肺炎球菌血清型的流行情况变化，并提高疫苗接种覆盖率。未来，基于对 PPV23 和新型肺炎球菌结合疫苗的长期免疫原性、临床效果和成本效益的比较评估，为老年人制定肺炎球菌疫苗接种建议将至关重要。
